Background. Despite an aggressive therapeutic approach, the prognosis for most patients with glioblastoma (GBM) remains poor. The aim of this study was to determine the significance of preoperative MRI variables, both quantitative and qualitative, with regard to overall and progression-free survival in GBM.
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, accounting for 53.9% of gliomas. 1 The current standard of care for newly diagnosed GBM involves surgery and concomitant regional radiotherapy with temozolomide (TMZ), followed by adjuvant TMZ. 2 Despite an aggressive therapeutic approach, the prognosis for most patients with GBM remains poor, with a median survival of 14.6 months and a 5-year survival rate of ,5%.
1,2
A number of variables have been found to influence patient prognosis-age, preoperative performance score, and extent of tumor resection are among the well-known variables. 3 -12 Currently, the extent of resection of enhancing tumor is one of the most important independent factors predicting survival in patients with GBM. 11 With advances in whole genome sequencing, molecular biomarkers have also been identified as impacting survival in GBM patients. 13 -17 Silencing of methylguanine-DNA methyltransferase is associated with longer survival in patients undergoing treatment with alkylating agents, such as TMZ. 13 Yan et al 14 showed that patients with tumors harboring isocitrate dehydrogenase (IDH) 1 or 2 mutations had a better outcome than those with IDH wild type. Multiple studies focusing on imaging correlates of survival in GBM patients are also available. 18 -30 Pope et al 21 evaluated the relationship between 15 descriptive MRI variables and survival in patients with anaplastic astrocytoma and GBM. Nonenhancing tumor, edema, multifocality, and satellite lesions were found to be indicators of poor outcome. Gutman et al 26 investigated a limited number of qualitative imaging variables; using 4 qualitative imaging features and a single measure of lesion size, the visually estimated proportion of contrast-enhancing tumor and longest axis length of tumor were found to be significantly associated with poor survival. Similarly, Nicolas-Jilwan et al 30 reported qualitative imaging features associated with overall survival (OS) and found that the proportion of contrastenhancing tumor significantly correlated with poor patient outcomes. No quantitative or volume-based parameters were analyzed; although some qualitative imaging parameters have been correlated with OS, progression-free survival (PFS) was not assessed; quantitative imaging metrics can increase the accuracy and reproducibility of tumor assessments, as these tumors are typically highly asymmetrical in morphology. 29 Further, although neuroimaging plays a pivotal role in diagnosis and monitoring of therapeutic response, the prognostic and predictive role of imaging characteristics of GBM has remained largely unmined.
Thus, the purpose of this study was to determine the significance of preoperative imaging variables, both quantitative and qualitative, with regard to survival outcomes (OS and PFS) in GBM patients; this study serves as the exhaustive imagingsurvival analysis study of The Cancer Genome Atlas (TCGA) GBM patient cohort using The Cancer Imaging Archive (TCIA). TCIA is a multi-institutional imaging repository, funded by the National Cancer Institute (NCI), corresponding to the GBM patient cohort (and other cancer cohorts) of TCGA and provides standardized imaging annotations. 26, 31, 32 In this study, we assess the OS and PFS significance in the 26 standardized preoperative qualitative and semi-quantitative imaging variables provided by the Visually Accessible Rembrandt Images (VASA-RI) research project, the largest preoperative imaging parameters to date, 33 and quantitative volume-based parameters as defined by Zinn et al. 34 This study nonselectively reports the entire standardized qualitative imaging parameters of the dataset of TCIA and associated volumetrics with regard to correlates and predictors of both OS and PFS.
Methods

Patient Population and Clinical Variables
In this study, we used the original material and data provided by TCGA, which is a publicly available resource containing multidimensional genomic and clinical information on GBM and other cancers. 31 The project in TCGA was conducted in compliance with regulations and policies for the protection of human subjects, and approvals by institutional review boards were appropriately obtained. The preoperative MRIs of the corresponding patients of the project in TCGA were made available for public download from TCIA, which was established by the collaboration between NCI and multiple institutions in the United States. 32 We retrospectively identified 94 treatment-naïve GBM patients from TCGA who had both clinical and imaging data available. The clinical variables consisted of age, gender, and Karnofsky performance status (KPS).
Qualitative and Semi-quantitative Imaging Analysis
The qualitative and semi-quantitative imaging dataset annotations were based upon the VASARI feature set for human glioma. This comprehensive feature set contains standardized terminologies of the most common features used to describe primary cerebral neoplasia on standard pre-and postcontrast enhanced MRI. 25,31 -33 The open-source PACS (picture archiving and communication system) workstation, the ClearCanvas platform (http://www.clearcanvas.ca/), was used for imaging assessments. Board-certified neuroradiologists (C.A.H., 16 y experience; S.N.H., 6 y; M.W., 7 y; P.R., 5 y; R.R.C., 3 y; and M.J., 4 y) were recruited and trained in the use of the feature set. A minimum of 3 different VASARI scores were obtained for each patient. The scores were then collected centrally in the NCI system and subsequently analyzed. The lists of VASARI imaging features, scoring values, and their definitions are summarized in Table 1 . 33 
Quantitative Volumetric Imaging Analysis
Image acquisition, volume selection, and sequence definition Preoperative fluid-attenuated inversion recovery (FLAIR) and postcontrast T1-weighted imaging (T1WI) data were downloaded from TCIA and used for segmentation of the 3 different GBM compartments, namely edema/tumor invasion, tumor, and necrosis. The area of peritumoral T2/FLAIR hyperintensity in GBM reflects an admixture of infiltrative tumor and vasogenic edema. For nomenclature purposes, this area is referred to as "edema/tumor invasion" in this study. Enhancement identified on postcontrast T1WI corresponds to an area of active viable tumor with disrupted blood -brain barrier; therefore, this area is defined as "tumor." The region within the tumor that does not show enhancement was defined as "necrosis"; and, thus, its volume was also quantified on postcontrast T1WI. Wangaryattawanich et al.: Imaging predictors of overall and progression-free survival in GBM Qualitative degree of contrast enhancement defined as having all or portions of the tumor that demonstrate significantly higher signal on the postcontrast T1W images compared with precontrast T1W images.
Proportion enhancing ,5%, 6%-33%, 34%-67%, 68%-95%, .95% Visually estimated proportion of enhancing component to the entire tumor Proportion nCET ,5%, 6%-33%, 34%-67%, 68%-95%, .95% Visually estimated proportion of nonenhancing component to the entire tumor Proportion necrosis ,5%, 6%-33%, 34%-67%, 68%-95%, .95% Visually estimated proportion of necrosis to the entire tumor. Necrosis is defined as a region within the tumor that does not enhance, is high on T2W and proton density images, is low on T1W images, and has an irregular border. Proportion of edema ,5%, 6%-33%, 34%-67%, 68%-95%, .95% Visually estimated proportion of edema to the entire tumor. Edema is defined as a region which is greater in signal than nCET and somewhat lower in signal than CSF. 34 for image visualization, analysis, and interactive segmentation. 35 -37 Tumor segmentation was performed in consensus by a neuroradiologist (R.R.C.) and a 
Image Registration and Segmentation
First, FLAIR and postcontrast T1WI sequences were aligned and registered to each other to overcome the differences in imaging parameters such as scanning angles and voxel thickness. Resampling of the FLAIR volume to the matrix of the T1WI series was performed in those cases where the voxel size of the FLAIR and T1WI were different. The images were adequately registered in most scans; and an error of registration ,2 mm was deemed acceptable. We then performed tumor segmentation in a simple hierarchical model of anatomy from peripheral to central (Fig. 1) . The volumes of each tumor compartment were subsequently computed automatically.
Statistical Modeling for Survival Analysis and Survival Prediction
OS was defined as the time between the date of pathological diagnosis and the date of death or the date of last clinical follow-up. PFS was measured from the date of the first surgery to the first recurrence of the disease. The univariable Cox proportional hazards model was used to determine hazard ratios (HRs) of each variable as a predictor of OS and PFS. Each variable that had a P-value ,.2 in the univariable analysis was selected to be included in a stepwise forward multivariable Cox regression analysis. All of the above steps were done for the VA-SARI features and volumetric features separately, as well as for the VASARI and volumetric features together (combined model). To evaluate the effect of age and KPS on each imaging feature in the combined multivariable model, we calculated the age-and KPS-adjusted HR. For all categorical and continuous variables that had more than 2 groups, a decision tree approach based on recursive partitioning analysis was applied to establish subgroups and cutoff values. This is a decision tree method for defining predictors. Each variable was examined for the best split, which was chosen to maximize the difference in the responses between the 2 branches of the split.
Receiver operating characteristic (ROC) analysis and area under the curve (AUC) were used to estimate the accuracy of the Cox models. All statistical analyses were performed using Stata v10. P ≤ .05 was considered statistically significant.
Results
Patient Population and Characteristics
Enrolled in the study were a total of 94 TCGA patients with GBM (31 female, 63 male; mean age 57.5; median age 59.5; range 14-84 y). The demographic and other characteristics of the included patients are summarized in Table 2 . KPS parameters were available in 73 patients.
Univariable and Kaplan -Meier Survival Analysis
With respect to clinical variables, age was a statistically significant prognostic factor for both OS (HR ¼ 1.025, 95% CI: 1.009-1.043, P ¼ .002) and PFS (HR ¼ 1.021, 95% CI: 1.003-1.039, P ¼ .036), Table 3) .
In the univariable analysis of the qualitative imaging variables (Table 3) , we found multiple imaging features that were significantly associated with both OS and PFS, namely major axis (longest diameter; OS, P ¼ .009; PFS, P ¼ .027), T1/FLAIR ratio (size of precontrast T1 abnormality compared with size of FLAIR abnormality) (OS, P ¼ .044; PFS, P ¼ .024), presence of ependymal extension (OS, P ¼ .004; PFS, P ¼ .005), deep white matter invasion (OS, P ¼ .007; PFS, P , .001), and contrast-enhancing tumor crossing midline (enhancing tumor invading into contralateral hemisphere through white matter commissures; OS, P ¼ .004; PFS, P ¼ .002). Presence of nonenhancing tumor crossing the midline (nonenhancing tissue crossing into contralateral hemisphere through white matter commissures) and satellite lesions (an area of enhancement within the region of signal abnormality surrounding the dominant lesion but not contiguous in any part with the major enhancing tumor mass) were found to be significant prognostic indicators for decreased PFS (P ¼ .03 and P , .001, respectively), while tumor location (frontal/parietal/temporal vs the rest) and tumor distribution (multifocal/multicentric vs focal) were significant for decreased OS (P ¼ .015 and P ¼ .029, respectively) ( Table 3 ). The survival difference with respect to VASARI features are shown in Figs 2 and 3 (and Supplementary Table S1 ).
The univariable analysis of the volumetric imaging features (Table 3) showed that volume of the enhancing tumor with cutoff of 35 000 mm 3 was a significant predictor of OS (P ¼ .013); the OS for patients with tumor volume of ,35 000 mm 3 was 14.3 months versus 8.4 months for patients with higher tumor volume (OS benefit ¼ 5.9 mo) ( Fig. 2; Supplementary  Table S1 ). The volume of edema/tumor invasion was also significantly associated with OS (P ¼ .019); patients with edema/ tumor invasion ,85 000 mm 3 had significantly longer OS (14.2 mo) in comparison with those who had edema/tumor invasion .85 000 mm 3 (9.7 mo). The proportion of enhancing tumor was the other volumetric feature that was significantly (P ¼ .038) associated with OS. Patients whose enhancing portion of the whole tumor was ≥24 had significantly lower OS (11.8 mo) versus the patients with enhancing portion of ,24% (14.7 mo). Regarding PFS, volume of enhancing tumor with cutoff of 24 850 mm 3 was a significant predictor for PFS (P ¼ .05) ( Fig. 3; Supplementary Table S2 ).
Multivariable Survival Analysis
Two separate sets of multivariable models, one for VASARI features and the other for volumetric features, were analyzed (Table 4 ). In the VASARI feature model alone, T1/FLAIR ratios, ependymal extension, and deep white matter invasion of tumor were significant independent prognostic indicators of OS (Ps ¼ .03, .02, and .006, respectively). Deep white matter invasion and distribution of tumor were significant predictors of PFS (P ¼ .007 and .003, respectively). Deep white matter invasion was significantly associated with 89% increased risk of death (HR ¼ 1.89, 95% CI: 1.20 -2.97) and 95% increased risk of disease progression (HR ¼ 1.95, 95% CI: 1.20-3.16).
For volumetric features, tumor proportion and edema/ tumor invasion volume were strongly associated with prediction of OS. One unit increase in tumor proportion resulted in an increased risk of death by 17 times (HR ¼ 17.21, P ¼ .004). Also, the risk of death was almost doubled in patients with edema/tumor invasion volume .85 000 mm 3 compared with those with lower edema/tumor invasion (HR ¼ 2.09, P ¼ .003). Tumor volume with a cutoff value of 24 850 mm 3 was significantly associated with PFS (HR ¼ 1.61, P ¼ .050).
The combined (VASARI and volumetric features) multivariable model (Table 4 ) demonstrated that tumor volume and eloquent brain involvement were independent variables for prediction of OS (Ps ¼ .03 and ,.001, respectively). Patients with tumor volume .35 000 mm 3 had 74% higher risk of death compared with patients with tumor volume ,35 000 mm 3 (HR ¼ 1.74, P ¼ .03). Deep white matter invasion remained a significant predictor of progression in the combined model (P ¼ .01). Multifocal/multicentric versus focal tumor was marginally associated with decreased PFS in the combined model (P ¼ .07).
To evaluate the effect of age and KPS on the predictive imaging features, we calculated age-and KPS-adjusted HRs for the final variables in the combined model (Table 4 ). The HRs and corresponding 95% CIs did not change significantly after adjustment (see Supplementary Fig. S1 ).
ROC analysis was performed to assess the accuracy of the combined predictive model of OS (see Supplementary  Fig. S2A ). The AUC was 79%, with CI of 63% -95%. Patients with eloquent brain involvement and tumor volume more than 35 000 mm 3 (final combined model variables) had significantly (P ¼ .002) lower OS (4.2 mo) versus the other patients (14.2 mo) (see Supplementary Fig. S5B ).
Discussion
This study serves as an exhaustive analysis correlating imaging with patient outcomes to include associations and predictors of OS and PFS in GBM patients, specifically the GBM patient cohort of TCGA. TCIA, resulting from TCGA efforts and funded by the Cancer Imaging Program of the National Institutes of Health, reflects a major step toward the establishment of an imaging database infrastructure, an organized collection of catalogued images, and a standardized imaging feature set that can be used for future similar efforts. The standardized qualitative imaging parameters provided by the VASARI feature set of TCIA, quantitative volumetric parameters provided by Zinn et al, 34 and clinical parameters in the GBM cohort of TCGA were 
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Neuro-Oncologyexhaustively analyzed. The prognostic role of these variables was systematically investigated. Importantly, this is the first study investigating the contribution to survival of quantitative volumetric (true 3D volumes) parameters, including specific cutoff values. We demonstrated that the volume of tumor enhancement (ie, active viable tumor with blood-brain barrier breakdown) was an important independent prognostic indicator for prediction of OS, even after adjustment for other imaging features. A larger extent of enhancing disease indicates higher tumor burden compared with lower extent resulting in patient's dismal prognosis. Iliadis et al 16 demonstrated that one unit increase in preoperative enhancing tumor was significantly associated with 1% increased risk of mortality (P ¼ .037) and progression (P ¼ .041); but no suitable cutoff value was presented for preoperative tumor volume. Concerning the influence of age and KPS, after adjustment for these factors, tumor volume still showed a marginally significant predictive effect for mortality (P ¼ .08). The patients who had an enhancing tumor volume lower than 35 000 mm 3 demonstrated longer OS benefit of 5.1 months compared with the patients who had a higher enhancing tumor volume (P ¼ .013).
With regard to the nonenhancing tumor component, we demonstrated that the volume of edema/tumor invasion with a cutoff value of 85 000 mm 3 was a significant predictor factor for mortality (P ¼ .003) among the volumetric features. It is well known that the areas of nonenhancing T2/FLAIR signal abnormality in GBM represent an admixture of bulk tumor invasion and vasogenic edema. These parameters serve as a surrogate marker for tumor invasiveness that partly determines extension of the nonenhancing infiltrative tumor. GBM with infiltrating phenotype also tends to have multifocal disease and poor survival. 15 Schoenegger et al 22 investigated the prognostic role of peritumoral edema in GBM patients. By using a simple measurement technique (,1 cm or .1 cm from the enhancing tumor margin), the patients were stratified into minor and major edema subgroups, respectively. They found that the major edema subgroup had significantly shorter OS compared with the minor edema subgroup. A number of studies with qualitative assessment of peritumoral edema/nonenhancing disease also reported that the presence and larger extent of peritumoral edema/invasion is a negative prognostic factor. 19, 21 To the best of our knowledge, our study is the first to identify the cutoff values of the volume-based imaging parameters (ie, enhancing tumor, necrosis, edema/tumor invasion) to predict individual outcome in GBM patients. We found that the volume-based parameter of edema/tumor invasion was an important independent prognostic factor. By using the single optimal cutoff of the edema/tumor invasion volume at 85 000 mm 3 , we found that the median OS benefit of those patients who had lower edema/invasion volume compared with those who had a higher volume was 4.6 months (median OS 14.3 mo vs 9.7 mo; P ¼ .019). These innovative findings introduce a new promising imaging biomarker for patients with GBM derived from volume-based parameters. This new prognostic stratification approach helps provide a more accurate prognosis for individual patients and can be used as a stratification tool in clinical trials.
Regarding the prognostic role of tumor necrosis, there are various results among the limited numbers of survival studies in GBM. 10, 19, 21, 24 Hammoud et al 19 found that the amount of tumor necrosis on preoperative scans was the strongest prognostic variable. This is similar to other retrospective studies 10, 24 ; however, our study showed no significant association between degree of tumor necrosis and survival. This can be attributed to differences in measurement and grading system, that is, Wangaryattawanich et al.: Imaging predictors of overall and progression-free survival in GBM quantitative and qualitative assessment. However, a better explanation can be found based on genomic differences. 38 In one of our previous studies, we found different mechanisms and pathways regulating cell death that appears to be sex specific, and in which the mechanism by which cell death occurs in GBM as defined by MRI (necrosis) appears to be driven by a more apoptotic (TP53) pathway in males; while in females, the mechanism by which this occurs appears to be due to a more oncogenic (MYCN) pathway. 38 With advancements in the understanding of genetic alterations and biology of GBM, ongoing radiogenomic studies may provide additional information regarding difference in survival and differential tumor responses by providing more comprehensive correlation between specific genetic aberrations and imaging features. Ongoing research in our group is currently investigating these topics.
With regard to the qualitative imaging features, deep white matter invasion was among the most important associated variables with survival, likely reflective of a more biologically aggressive and advanced tumor. In our study, we found that this imaging feature is associated with a shorter PFS, independently and significantly. Even after adjustment for age and KPS, the HR remained significant (P before age and KPS adjustment ¼ 0.01 and after adjustment ¼ 0.04), which showed the strong predictive effect of this invasive imaging feature. A more recent study 39 demonstrated that patients with an invasive imaging signature have a significant decrease in OS and an associated specific genomic expression profile that may explain the mechanism of this spread pattern.
In our study, even though multifocal tumor was not associated with PFS significantly in the final models (P ¼ .07), it was selected in a stepwise model of VASARI features alone as well as in the combined model. The latter demonstrates the predictive power of this feature versus other VASARI features. The clinical significance of this feature has been well established in both the radiology and nonradiology literature. 21, 39, 40 Pope et al 21 retrospectively investigated the prognostic significance of certain MRI features in patients with high-grade gliomas and found that the presence of multifocal tumor was one of the significant negative prognostic indicators. Multiple lesions were also found to be associated with lower KPS and inability to perform gross total resection in a retrospective study. 39 More recent published literature 40 also addressed the importance of this feature and showed that patients with a single focal tumor had a statistically significantly better PFS compared with the multifocal group; however, there was no statistically significant difference in OS, similar to our results.
There are some limitations in our study. Our study is inherently limited by its retrospective design using a preexisting database and images acquired from different scanners from various hospitals involved in data collection by TCGA. However, this dataset as well as the standardized VASARI feature set and validated segmentation technique as described by Zinn et al Wangaryattawanich et al.: Imaging predictors of overall and progression-free survival in GBM reflects a standardized comprehensive and validated methodology leveraging the concerted efforts of TCIA. Using the database of TCGA, we could not consider some parameters like the extent of tumor resection and the extent of the initial TMZ chemotherapy in our analyses. Despite these limitations, our study demonstrates the value of imaging features in predicting patient outcomes. However, a prospective study design is needed to validate the prognostic utility of these potential imaging biomarkers. Further, additional imaging variables such as radiomic analysis and texture analysis of the tumor can be anticipated to Wangaryattawanich et al.: Imaging predictors of overall and progression-free survival in GBM increase the prognostic predictive power of imaging. Additionally, advanced functional MRI such as diffusion imaging and perfusion imaging with quantitative hemodynamic parameters of tumor-for instance, maximum tumor blood volume-are shown to be significantly associated with patient OS 27 and could be used as prognostic indicators. Such studies are under way in our group. 41 -43 Our comprehensive TCGA imaging-outcome analysis establishes the prognostic significance of pretreatment imaging variables and provides specific cutoff values by which clinical decision making can be performed and precision medicine leveraged. This sets the groundwork needed for development of robust imaging biomarkers that can potentially be applied to current classification models and routine clinical practice. The power of TCGA imaging datasets with structured imaging features provided by the VASARI feature set and the GBM volumetrics as defined by Zinn et al 34 sets the stage for a new era of personalized qualitative and quantitative feature assessments and reporting; these parameters and cutoff volumetric volumes can serve as a template for future imaging and imaging genomic applications and discoveries as these harbor prognostic significance.
In summary, specific preoperative MRI features and signatures have a significant prognostic role in helping to predict survival in patients with GBM. Given the statistical prognostic significance, specific preoperative MRI brain tumor features can now be considered for prognostic imaging genomic biomarker development and validation. Imaging signatures derived from these features can potentially be used for patient stratification and endpoint prognostic biomarkers in prospective clinical trials.
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